Developer docs
API playgroundTry for free, no card

Search company profiles

Biologics

Full company profile

uuid000mayr

Namestring
Biologics
Legal namestring
Biologics by McKesson
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Biologics by McKesson is an independent specialty pharmacy subsidiary of McKesson Corporation (NYSE: MCK), headquartered in Cary, North Carolina. Founded in 1994 as the nation's first cancer-focused specialty pharmacy, the company dispenses specialty medications across three core therapy areas: oncology, rare and orphan diseases, and cell and gene therapy. It manages over 200 specialty therapies, including 130 limited distribution medications and 100+ oral therapies, supported by 30,000 active provider relationships and 500+ payer network contracts, with a reported 98% patient satisfaction rate.

The platform combines specialty pharmacy dispensing with an integrated suite of hub services, including access and reimbursement support, affordability programs, case management and adherence, non-commercial dispensing, provider engagement, biopharma reporting and insights, and technology integration. For cell and gene therapy specifically, Biologics leverages InspiroGene by McKesson, the parent company's center of excellence, to provide cold-chain infrastructure and specialized patient support. The technology stack is purpose-built for specialty prescription workflows, including prior authorizations, appeals processing, and patient adherence monitoring, and is delivered through dedicated provider and patient portals.

Biologics generates revenue through two primary streams: transaction-based specialty pharmacy dispensing (drug reimbursement and dispensing fees) and managed services hub contracts with biopharma manufacturers. Its customer base spans three primary segments: patients and families navigating complex medication journeys, healthcare providers needing specialty prescription support, and biopharma partners launching high-value specialty drugs. The company holds URAC Specialty Pharmacy Accreditation, ACHC Gold Seal of Accreditation, ACHC Oncology accreditation, and NASP corporate membership.

Short descriptiontext

Biologics by McKesson is an independent specialty pharmacy subsidiary of McKesson Corporation dispensing oncology, rare disease, and cell and gene therapies, supported by integrated hub services for biopharma manufacturers across 30,000 provider relationships and 500 payer contracts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmacy services, oncology pharmacy dispensing, cell and gene therapy support, biopharma hub services, rare disease pharmacy
Industry3 codes
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Ambulatory Health Care Services621
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmacy Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Specialty Pharmacy Dispensing
TypeTransaction Fee
Description

Biologics dispenses specialty medications including exclusive and limited distribution drugs, generating revenue through pharmacy dispensing fees and drug reimbursement.

biologics.mckesson.com
2Hub Services for Biopharma Partners
TypeManaged Services
Description

Biologics provides patient hub services including access and reimbursement support, affordability programs, case management, provider engagement, and biopharma reporting and insights. Revenue generated through contracted service agreements with biopharma manufacturers.

biologics.mckesson.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biologics by McKesson operates an independent specialty pharmacy that dispenses oncology, rare disease, and cell and gene therapy medications to patients while delivering integrated hub services to biopharma manufacturers. The company supports 200+ therapies including 130 limited distribution drugs and provides access/reimbursement support, affordability programs, case management, and provider engagement services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98% patient satisfaction rate
+3 more records
Product overview1 text field

Biologics by McKesson is an independent specialty pharmacy operating as a platform of integrated services across three core therapy areas: Oncology, Rare & Orphan Diseases, and Cell & Gene Therapy. The platform is built around core dispensing services complemented by a suite of Hub Services modules including Access & Reimbursement, Affordability Support, Case Management & Adherence, Non-Commercial Dispensing, Provider Engagement, Biopharma Reporting & Insights, and Technology & Integration. The specialty pharmacy manages over 200 therapies including 130 limited distribution medications and 100 oral therapies including oral oncolytics. Key sub-brands include Pharmacy Elite (hub services for biopharma partners) and InspiroGene (McKesson's cell and gene therapy center of excellence that Biologics leverages for CGT support). The company also operates patient-facing services including financial assistance, patient advocacy support, and clinical adherence programs, alongside provider-facing tools including prescribing support, risk-based care programs, and specialty drug lists.

Product and service7 records
1Specialty Pharmacy Services - Oncology
CategorySpecialty Pharmacy
Description

Personalized specialty pharmacy support for high-volume oncology therapies, including dispensing, clinical support, and access services for cancer patients and their providers.

2Specialty Pharmacy Services - Rare & Orphan Diseases
CategorySpecialty Pharmacy
Description

Specialty pharmacy services with disease- and therapy-aligned teams trained on rare diseases, orphan therapies, and patient populations including children and teens.

3Cell & Gene Therapy Services
CategorySpecialty Pharmacy
Description

Specialty pharmacy dispensing and patient hub services for high-risk cell and gene therapies, including cold-chain logistics and clinical support.

4Pharmacy Elite Hub Services
CategoryHub Services
Description

Comprehensive hub services for biopharma partners, bundling access/reimbursement, affordability, case management, provider engagement, biopharma reporting, and technology integration.

5InspiroCare Hub Services
CategoryHub Services
Description

Specialized hub services for cell and gene therapy biopharma partners, providing purpose-built patient support, commercialization, and access services.

6Specialty Drugs List
CategorySpecialty Pharmacy
Description

Over 200 specialty therapies including 130 limited distribution medications and 100+ oral therapies covering cancer and rare/complex diseases, accessible through the provider portal.

7Patient Financial Assistance Program
CategoryPatient Support Services
Description

Financial assistance services connecting patients with grants and support programs to reduce out-of-pocket costs for specialty medications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Rigel Pharmaceuticals
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-02
Description

Biologics by McKesson's Pharmacy Elite was awarded the hub contract by Rigel Pharmaceuticals to provide hub services for Tavalisse, Gavreto, and Rezlidhia.

biologics.mckesson.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Biologics partners with InspiroGene by McKesson, a center of excellence for cell and gene therapy, to provide integrated pharmacy and hub services for high-risk cell and gene therapies.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Biologics by McKesson, in partnership with InspiroGene, was selected by Precigen to support specialty pharmacy and patient hub services for the launch of a novel immunotherapy.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-24
Description

Biologics by McKesson was chosen as the exclusive specialty pharmacy partner for Amtagvi (lifileucel), the first FDA-approved cell therapy for solid tumors.

5McKesson
Strategic tierCoreTypeOthers
Description

Biologics is an independent specialty pharmacy and subsidiary of McKesson Corporation, leveraging McKesson's distribution network, scale, and infrastructure including cold-chain capabilities for cell and gene therapy.

biologics.mckesson.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Accredo is the largest U.S. specialty pharmacy by volume, owned by Express Scripts/Cigna. It competes with Biologics across oncology, rare disease, and CGT, and benefits from captive PBM patient flow.

TypeBroad incumbent
Description

Diplomat was a leading independent specialty pharmacy in oncology and rare diseases before being acquired by Optum/UnitedHealth; it now competes with Biologics as part of Optum's vertically integrated specialty platform.

TypeDirect peer
Description

Onco360 is one of the largest independent oncology-focused specialty pharmacies in the U.S., competing head-to-head with Biologics for oncology dispensing contracts and limited distribution drug assignments.

TypeDirect peer
Description

US Bioservices is a specialty pharmacy and hub-services provider owned by Cencora (formerly AmerisourceBergen), competing directly with Biologics in oncology, rare disease, and biopharma hub services.

TypeDirect peer
Description

Bioplus is an independent specialty pharmacy focused on oncology, hematology, and rare diseases, offering dispensing and hub services that directly overlap with Biologics' core offerings.

TypeBroad incumbent
Description

Walgreens Specialty Pharmacy is a large-scale specialty pharmacy provider within Walgreens Boots Alliance, competing in oncology and complex therapy dispensing with national retail-pharmacy reach.

TypeDirect peer
Description

PantherRx Rare is a specialty pharmacy exclusively focused on rare and orphan disease therapies, directly competing with Biologics' rare disease franchise and limited distribution medications.

TypeBroad incumbent
Description

CVS Specialty is the specialty pharmacy arm of CVS Health, offering broad specialty dispensing and hub services with strong payer integration via CVS Caremark — a significant competitor in the same therapy areas as Biologics.

9Amber Specialty Pharmacy
TypeDirect peer
Description

Amber Specialty Pharmacy is a Hy-Vee-owned specialty pharmacy providing oncology, rare disease, and infusion therapies with hub services, positioning it as a direct mid-market competitor to Biologics.

TypeEmerging player
Description

CPS operates specialty and hospital pharmacy programs including limited distribution drug services, with partial overlap to Biologics in complex therapy support and provider-facing pharmacy services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biologics

Specialty Pharmacy Servicesbiologicsinc.com

Biologics by McKesson is an independent specialty pharmacy subsidiary of McKesson Corporation dispensing oncology, rare disease, and cell and gene therapies, supported by integrated hub services for biopharma manufacturers across 30,000 provider relationships and 500 payer contracts.

What Biologics does

Biologics by McKesson is an independent specialty pharmacy subsidiary of McKesson Corporation (NYSE: MCK), headquartered in Cary, North Carolina. Founded in 1994 as the nation's first cancer-focused specialty pharmacy, the company dispenses specialty medications across three core therapy areas: oncology, rare and orphan diseases, and cell and gene therapy. It manages over 200 specialty therapies, including 130 limited distribution medications and 100+ oral therapies, supported by 30,000 active provider relationships and 500+ payer network contracts, with a reported 98% patient satisfaction rate.

The platform combines specialty pharmacy dispensing with an integrated suite of hub services, including access and reimbursement support, affordability programs, case management and adherence, non-commercial dispensing, provider engagement, biopharma reporting and insights, and technology integration. For cell and gene therapy specifically, Biologics leverages InspiroGene by McKesson, the parent company's center of excellence, to provide cold-chain infrastructure and specialized patient support. The technology stack is purpose-built for specialty prescription workflows, including prior authorizations, appeals processing, and patient adherence monitoring, and is delivered through dedicated provider and patient portals.

Biologics generates revenue through two primary streams: transaction-based specialty pharmacy dispensing (drug reimbursement and dispensing fees) and managed services hub contracts with biopharma manufacturers. Its customer base spans three primary segments: patients and families navigating complex medication journeys, healthcare providers needing specialty prescription support, and biopharma partners launching high-value specialty drugs. The company holds URAC Specialty Pharmacy Accreditation, ACHC Gold Seal of Accreditation, ACHC Oncology accreditation, and NASP corporate membership.

Biologics firmographics

Firmographics
Name
Biologics
Legal name
Biologics by McKesson
Website
https://biologicsinc.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
101–250 employees
Short description
Biologics by McKesson is an independent specialty pharmacy subsidiary of McKesson Corporation dispensing oncology, rare disease, and cell and gene therapies, supported by integrated hub services for biopharma manufacturers across 30,000 provider relationships and 500 payer contracts.
Ownership category
akta.pro rank

Biologics industry classification

Industry
Product category
Specialty Pharmacy Services
NAICS
Ambulatory Health Care Services (621)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Specialty pharmacy services
  • Oncology pharmacy dispensing
  • Cell and gene therapy support
  • Biopharma hub services
  • Rare disease pharmacy

Where Biologics is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Specialty Pharmacy Dispensing: Biologics dispenses specialty medications including exclusive and limited distribution drugs, generating revenue through pharmacy dispensing fees and drug reimbursement.
  2. Hub Services for Biopharma Partners: Biologics provides patient hub services including access and reimbursement support, affordability programs, case management, provider engagement, and biopharma reporting and insights. Revenue generated through contracted service agreements with biopharma manufacturers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Biologics product offering

Product offering

Core offering

Biologics by McKesson operates an independent specialty pharmacy that dispenses oncology, rare disease, and cell and gene therapy medications to patients while delivering integrated hub services to biopharma manufacturers. The company supports 200+ therapies including 130 limited distribution drugs and provides access/reimbursement support, affordability programs, case management, and provider engagement services.

Product overview

Biologics by McKesson is an independent specialty pharmacy operating as a platform of integrated services across three core therapy areas: Oncology, Rare & Orphan Diseases, and Cell & Gene Therapy. The platform is built around core dispensing services complemented by a suite of Hub Services modules including Access & Reimbursement, Affordability Support, Case Management & Adherence, Non-Commercial Dispensing, Provider Engagement, Biopharma Reporting & Insights, and Technology & Integration. The specialty pharmacy manages over 200 therapies including 130 limited distribution medications and 100 oral therapies including oral oncolytics. Key sub-brands include Pharmacy Elite (hub services for biopharma partners) and InspiroGene (McKesson's cell and gene therapy center of excellence that Biologics leverages for CGT support). The company also operates patient-facing services including financial assistance, patient advocacy support, and clinical adherence programs, alongside provider-facing tools including prescribing support, risk-based care programs, and specialty drug lists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Specialty Pharmacy Services - Oncology Personalized specialty pharmacy support for high-volume oncology therapies, including dispensing, clinical support, and access services for cancer patients and their providers.
  • Specialty Pharmacy Services - Rare & Orphan Diseases Specialty pharmacy services with disease- and therapy-aligned teams trained on rare diseases, orphan therapies, and patient populations including children and teens.
  • Cell & Gene Therapy Services Specialty pharmacy dispensing and patient hub services for high-risk cell and gene therapies, including cold-chain logistics and clinical support.
  • Pharmacy Elite Hub Services Comprehensive hub services for biopharma partners, bundling access/reimbursement, affordability, case management, provider engagement, biopharma reporting, and technology integration.
  • InspiroCare Hub Services Specialized hub services for cell and gene therapy biopharma partners, providing purpose-built patient support, commercialization, and access services.
  • Specialty Drugs List Over 200 specialty therapies including 130 limited distribution medications and 100+ oral therapies covering cancer and rare/complex diseases, accessible through the provider portal.
  • Patient Financial Assistance Program Financial assistance services connecting patients with grants and support programs to reduce out-of-pocket costs for specialty medications.

Quantifiable outcome

  • 98% patient satisfaction rate
  • +3 more outcomes

Companies that use Biologics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Biologics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biologics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Rigel PharmaceuticalsmajorStrategic or Co-development Partner · 2 January 2026Biologics by McKesson's Pharmacy Elite was awarded the hub contract by Rigel Pharmaceuticals to provide hub services for Tavalisse, Gavreto, and Rezlidhia.
  • InspiroGene by McKessoncoreStrategic or Co-development Partner · 25 September 2025Biologics partners with InspiroGene by McKesson, a center of excellence for cell and gene therapy, to provide integrated pharmacy and hub services for high-risk cell and gene therapies.
  • PrecigenmajorStrategic or Co-development Partner · 25 September 2025Biologics by McKesson, in partnership with InspiroGene, was selected by Precigen to support specialty pharmacy and patient hub services for the launch of a novel immunotherapy.
  • Iovance BiotherapeuticsmajorChannel Partner/ Reseller/ Distributor · 24 September 2025Biologics by McKesson was chosen as the exclusive specialty pharmacy partner for Amtagvi (lifileucel), the first FDA-approved cell therapy for solid tumors.
  • McKessoncoreOthersBiologics is an independent specialty pharmacy and subsidiary of McKesson Corporation, leveraging McKesson's distribution network, scale, and infrastructure including cold-chain capabilities for cell and gene therapy.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Biologics competitors and assessment

Company assessment

Broad incumbents

  • Accredo (Express Scripts): Accredo is the largest U.S. specialty pharmacy by volume, owned by Express Scripts/Cigna. It competes with Biologics across oncology, rare disease, and CGT, and benefits from captive PBM patient flow.
  • Diplomat Pharmacy (Optum Specialty): Diplomat was a leading independent specialty pharmacy in oncology and rare diseases before being acquired by Optum/UnitedHealth; it now competes with Biologics as part of Optum's vertically integrated specialty platform.
  • Walgreens Specialty Pharmacy: Walgreens Specialty Pharmacy is a large-scale specialty pharmacy provider within Walgreens Boots Alliance, competing in oncology and complex therapy dispensing with national retail-pharmacy reach.
  • CVS Specialty: CVS Specialty is the specialty pharmacy arm of CVS Health, offering broad specialty dispensing and hub services with strong payer integration via CVS Caremark — a significant competitor in the same therapy areas as Biologics.

Direct peers

  • Onco360: Onco360 is one of the largest independent oncology-focused specialty pharmacies in the U.S., competing head-to-head with Biologics for oncology dispensing contracts and limited distribution drug assignments.
  • US Bioservices (AmerisourceBergen / Cencora): US Bioservices is a specialty pharmacy and hub-services provider owned by Cencora (formerly AmerisourceBergen), competing directly with Biologics in oncology, rare disease, and biopharma hub services.
  • Bioplus Specialty Pharmacy: Bioplus is an independent specialty pharmacy focused on oncology, hematology, and rare diseases, offering dispensing and hub services that directly overlap with Biologics' core offerings.
  • PantherRx Rare: PantherRx Rare is a specialty pharmacy exclusively focused on rare and orphan disease therapies, directly competing with Biologics' rare disease franchise and limited distribution medications.
  • Amber Specialty Pharmacy: Amber Specialty Pharmacy is a Hy-Vee-owned specialty pharmacy providing oncology, rare disease, and infusion therapies with hub services, positioning it as a direct mid-market competitor to Biologics.

Emerging players

  • CPS Solutions (Comprehensive Pharmacy Services): CPS operates specialty and hospital pharmacy programs including limited distribution drug services, with partial overlap to Biologics in complex therapy support and provider-facing pharmacy services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Biologics social profiles

Digital presence

Biologics compliance and trust

Trust signal

Compliance4 records

Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biologics leadership team

Management profile

Number of profiles

Profiles2 records

Biologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biologics

What does Biologics do?

Biologics by McKesson operates an independent specialty pharmacy that dispenses oncology, rare disease, and cell and gene therapy medications to patients while delivering integrated hub services to biopharma manufacturers. The company supports 200+ therapies including 130 limited distribution drugs and provides access/reimbursement support, affordability programs, case management, and provider engagement services.

Is Biologics a public or private company?

Biologics is a private company. It is classified as corporate owned and is currently operating.

When was Biologics founded?

Biologics was founded in 1994. It employs 101 to 250 people.

Where is Biologics based?

Biologics is headquartered in Cary, United States, in the North America region.

How does Biologics make money?

Two revenue lines are on record. Specialty Pharmacy Dispensing is the primary driver. The others are hub Services for Biopharma Partners.

Who are Biologics's main competitors?

Broad incumbents on record are Accredo (Express Scripts), Diplomat Pharmacy (Optum Specialty), Walgreens Specialty Pharmacy and CVS Specialty. Direct peers are Onco360, US Bioservices (AmerisourceBergen / Cencora), Bioplus Specialty Pharmacy, PantherRx Rare and Amber Specialty Pharmacy. CPS Solutions (Comprehensive Pharmacy Services) is listed as an emerging player.

Does Biologics have an API?

No public API is recorded for Biologics.

What industry is Biologics in?

Biologics's product category is Specialty Pharmacy Services. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 621 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileAn Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar MarketsDyadic Applied BioSolutions (NASDAQ: DYAI) is advancing its next growth phase by expanding commercialization of its protein production platform across Life Sciences, Food & Nutrition, and Bio-industrial markets, with products already launched through partners including ProLiant Health and Biologics. The company is leveraging its proprietary Dapibus™ and C1 expression systems to enable scalable, non-animal protein production for customers. President and COO Joe Hazelton outlined the company's focus on building recurring revenue streams while addressing growing global demand for sustainable protein solutions.NewswireLeading Talent Steve Pruitt Joins Biologics ModularBiologics Modular hired Steve Pruitt as Construction Manager, a 38-year veteran with experience at Indy Walls & Ceilings, which reported $20 million in annual revenue. He will streamline construction processes and support expansion into modular wall systems for pharmaceutical and healthcare clients.BioSpaceBiologics Market Size to Witness Significant Growth by 2024 endTransparency Market Research forecasts the global biologics market to reach $479.7 billion by 2024, up from $231.2 billion in 2017, at a 10.9% CAGR. Monoclonal antibodies are expected to lead growth at 11.9% CAGR, with North America holding over 40% share.BioSpaceFibroBiologics Announces Inaugural Board of DirectorsFibroBiologics announced its inaugural board of directors on Aug. 6, 2021, led by Chairman Pete O'Heeron. The board includes executives from GlycosBio, Immunogen, Kintara Therapeutics, Orion Healthcare Advisors, and Takeda. The company is developing fibroblast-based therapies for degenerative disc disease, orthopedics, multiple sclerosis, and cancer.NewswireBialogics Analytics Converts 20 Years of Diagnostic Reporting to Facilitate Clinical Research and Operational Analytics in Medical ImagingBialogics Analytics implemented its DxPro Clinical and Operational Analytics Solution at The Hospital for Sick Children, converting 20 years of radiology reporting into a unified database of 2.5 million diagnostic reports. The structured, searchable database supports research, clinical, and operational analytics, including cohort identification and AI/ML development.The Pharma LetterProtalix and Chiesi submit Fabry disease BLA to FDAProtalix BioTherapeutics and Chiesi submitted a Biologics License Application to the FDA for pegunigalsidase alfa to treat Fabry disease. The submission was made via the accelerated approval pathway, following the drug's fast track designation in January 2018.PrwebCatalent Biologics Completes $14 Million Commercial Packaging Expansion at its Bloomington, Indiana FacilityCatalent completed a $14 million expansion at its Bloomington, Indiana biologics facility, adding 15,000 square feet and five new packaging suites. The expansion includes three new high-speed packaging lines for vials, syringes, and devices, with no glass-to-glass contact.PrwebRegen Suppliers Now Offering 20% Discount On Biologics Orders to New CustomersRegen Suppliers is offering first-time customers a 20% discount on initial biologics orders, including stem cell and exosome products. The company also provides PRP kits, PDO thread lifts, and training courses. The discount applies to qualifying medical providers.News-MedicalRheumatoid arthritis: biologics useful in young and old alikeA study of nearly 7,200 RA patients found biologics are equally effective and safe in elderly-onset and young-onset rheumatoid arthritis. Improvement rates, disease activity, and drug retention were comparable at 48 weeks, though remission rates were lower in the elderly group. Researchers plan to test different biologic modes in elderly patients.NewswireErosion of Physician and Patient Treatment Choice Continues - Alliance for Safe Biologic Medicines Raises Concerns for Patients as British Columbia Expands Biologics Forced Switching PolicyBritish Columbia's government will forcibly switch 1,700 IBD patients and 20,700 arthritis, psoriasis, and diabetes patients from their biologic medicines to biosimilars, ceasing reimbursement of the originals. The Alliance for Safe Biologic Medicines and patient groups oppose the policy, citing loss of physician and patient choice, which is rare in advanced nations.